Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study

BACKGROUND: Tenofovir disoproxil (TDF) is a promising salvage therapy for patients with chronic hepatitis B (CHB) who failed regimens of other nucleoside analogues (NAs). In this study, we aimed to investigate the clinical efficacy and safety of TDF monotherapy in Chinese CHB patients with genotypic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jing, Liu, Yue-Ying, Lian, Jiang-Shan, Pan, Li-Fang, Yang, Jian-Le, Huang, Jian-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407037/
https://www.ncbi.nlm.nih.gov/pubmed/28397720
http://dx.doi.org/10.4103/0366-6999.204107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407037/
https://www.ncbi.nlm.nih.gov/pubmed/28397720
http://dx.doi.org/10.4103/0366-6999.204107

Ejemplares similares